drugset / Trial / NCT05985694
AD17002 Treating Poorly Controlled, Moderate to Severe Eosinophilic Asthma
Phase 1/2
Completed
40 enrolled
Advagene Biopharma Co. Ltd.
Taipei Medical University Hospital · collab
RandomizedParallel-groupSingle-blindTreatment
Summary
This clinical trial aims to investigate patients with poorly controlled, moderate to severe eosinophilic asthma. The main questions it seeks to answer are 1. Could the AD17002 intranasal immunomodulator improve the clinical condition of eosinophilic asthmatic patients? 2. Could patients self-administer AD17002 via the intranasal route? 3. Is the AD17002 at multiple doses safe for asthmatic patients? 4. Participants will be asked to self-administer two doses per week for a total of 6 weeks (11 doses). A diary on AD17002 usage, adverse events, and reliever medication will be recorded.
Timeline
- Start
- 2023-11-27
- Primary completion
- 2025-01-28
- Completion
- 2025-04-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | AD17002 | Protein / enzyme biologic | 10 ug | Intranasal |
| Subject | AD17002 | Protein / enzyme biologic | 20 ug | Intranasal |
Indications
No indication recorded.